METiS TechBio-P's stock plummeted 8.23% during intraday trading on Wednesday, continuing a downward trend for the newly listed company.

The decline follows a sustained pullback since the company's debut on the Hong Kong Exchange earlier this month. METiS TechBio, which bills itself as the world's first AI drug delivery stock, remains in early-stage commercialization with approximately RMB 1.5 billion in accumulated losses over the past three years and volatile revenue, leaving its growth trajectory unvalidated.

Adding to the selling pressure, certain internationally placed shares carry no lock-up period, creating persistent profit-taking opportunities for early investors. As initial enthusiasm for the new stock fades, the share price continues to face downward pressure from these combined factors.